Necrotic survivors and plasma membrane integrity signaling
Project Number1DP2GM146320-01
Former Number1DP2OD030566-01
Contact PI/Project LeaderGONG, YI-NAN
Awardee OrganizationUNIVERSITY OF PITTSBURGH AT PITTSBURGH
Description
Abstract Text
PROJECT SUMMARY/ABSTRACT
After decades of cell death study, it is now well accepted that cell death can be highly programmed,
including some lytic forms. For example, the plasma membrane (PM) pore-forming executor for
necroptosis is MLKL, when phosphorylated by RIPK3. For pyroptosis, gasdermin family members
are the PM damaging executors, once processed by caspases or granzymes. Intriguingly, the PM
pore-forming is not the “point of no return” for necroptosis or pyroptosis. This is because ESCRT-
III complex can repair the damaged PM by membrane remodeling. The broken PM fractions can
be shed off. Therefore, for both necroptotic and pyroptotic cells, they can tolerate a limited level
of PM damage and survive for a long time if ESCRT-III repairing capacity is not overwhelmed. In
this grant, we presented our UNPUBLISHED data showing if a necrotic cell can manage to stay
alive, the sub-lethal PM damage is sufficient to initiate a sophisticated signal transduction network.
We named this signaling transduction pathway as Plasma Membrane Integrity signaling (PMI
signaling). PMI signals are efficient in promoting pro-tumor chemokines/cytokines secretions. We
hypothesize that the necrotic “survivors” can stimulate oncogenesis via the PMI signaling pathway
and the consequent chemokines/cytokines paracrine. Our ultimate goal is to mechanistically
understand and further target these “survivors” to improve cancer treatment. To achieve this end,
we will firstly hunt for the sensors for PM integrity loss. We proposed to test a promising ion
channel candidate that is very likely to be one of the sensors for PM damage. We have also
planned an elegant cell culture system to perform both siRNA and sgRNA screen to search for
the PM damage sensors genome-wide. Next, we will use both animal models and human
specimens to probe the necrotic “survivors.” We will further test the roles of the
chemokines/cytokines secreted by these “survivors” in tumorigenesis and metastasis. Third, we
will try to eliminate the necrotic “survivors” directly. Our preliminary data lead us to a candidate
RING E3 ligase. We will test whether targeting this E3 ligase can help us suppress the ESCRT-
III repair action and eradicate necrotic “survivors.” As the necrotic “survivors” were only
discovered not long ago (by us and others), the massive impacts of cell death “survivors” in
contributing to cancers, transplantation, and other illnesses are still fresh and needed to be fully
defined. Innovative research, like this one, will promote the revelation.
Public Health Relevance Statement
PROJECT NARRATIVE
Most cell death studies are focused on how cells die, while this study focuses on the cells that
suffer from programmed necrosis but can survive. We hypothesize that the necrotic “survivors”
can stimulate oncogenesis via chemokines/cytokines secretions. We will reveal the molecular
mechanisms of the “necrotic survivors” and further target these “survivors” to improve cancer
treatments.
No Sub Projects information available for 1DP2GM146320-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1DP2GM146320-01
Patents
No Patents information available for 1DP2GM146320-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1DP2GM146320-01
Clinical Studies
No Clinical Studies information available for 1DP2GM146320-01
News and More
Related News Releases
No news release information available for 1DP2GM146320-01
History
No Historical information available for 1DP2GM146320-01
Similar Projects
No Similar Projects information available for 1DP2GM146320-01